Cyprus vs Gambia: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Cyprus
83.0%
in 2025
Gambia
82.0%
in 2025
Cyprus rank
102nd
Gambia rank
104th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Cyprus
- Gambia
How they compare
Cyprus currently reports 83.0% against 82.0% in Gambia, a difference of 1.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was Gambia ahead.
Cyprus ranks 102nd and Gambia ranks 104th of 192 countries.
Across the 3 decades both report, Cyprus averaged higher in 1 and Gambia in 1.
Head to head by decade
| Decade | Cyprus | Gambia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 40.5% | 94.6% | 54.1% | Gambia |
| 2020s | 80.3% | 79.7% | 0.7% | Cyprus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Cyprus or Gambia?
- Cyprus, at 83.0% against 82.0% in Gambia as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Cyprus and Gambia?
- 1.0%, with Cyprus ahead.
- How many years of comparable data are there for Cyprus and Gambia?
- 18 years are reported by both, from 2008 to 2025.
- How do Cyprus and Gambia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Cyprus ranks 102nd and Gambia ranks 104th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.